CCR9 and acute lymphoblastic leukemia: Finally, xenotransplants with a third primary T-ALL (T-ALL10) expressing ~1% of the CCR9 levels present in the MOLT4 cells (Figure 4C), treatment with 92R mAb still showed significant (p=0.000126) survival differences with the isotype control mAb treated group (estimated survivals of 61.7 ± 0.3 and 64.9 ± 0.5 days, respectively) (Figure 4C) Taken together, these data suggest that the treatment with 92R mAb is also effective in primary T-ALL cells, and the increase on survival directly correlates with the expression levels of CCR9 on the surface of the cells.